News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pozen, Inc. Reports Second Quarter Profit; Results Reflect $20 Million Milestone Payment For VIMOVO(TM)
August 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Artificial intelligence
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
September 25, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
September 24, 2026
·
2 min read
·
Nick Paul Taylor
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
September 24, 2026
·
2 min read
·
Gabrielle Masson
Funding
Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs
September 24, 2026
·
1 min read
·
Tristan Manalac
